|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| C07K 14/70596 | (2013.01) | ||
| C07K 14/705 | (2006.01) | ||
| C07K2319/30 | (2013.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61P 37/02 | (2018.01) |
| (11) | Number of the document | 3630158 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18806547.8 |
| Date of filing the European patent application | 2018-05-21 | |
| (97) | Date of publication of the European application | 2020-04-08 |
| (45) | Date of publication and mention of the grant of the patent | 2022-07-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/033728 |
| Date | 2018-05-21 |
| (87) | Number | WO 2018/217659 |
| Date | 2018-11-29 |
| (30) | Number | Date | Country code |
| 201762509498 P | 2017-05-22 | US |
| (72) |
LIU, Yang , US
ZHENG, Pan , US
DEVENPORT, Martin , US
LIU, Mingyue , US
|
| (73) |
Oncoimmune, Inc. ,
9430 Key West Avenue
Suite 113, Rockville, Maryland 20850,
US
Children's National Medical Center , 111 Michigan Avenue N.W., Washington, DC 20010, US |
| (54) | METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE EVENTS IN CANCER THERAPIES |
| METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE EVENTS IN CANCER THERAPIES |